20 articles
New research shows brief fasting periods can boost the effectiveness of cancer immunotherapy by reshaping tumor-fighting immune cells.
New fusion model combines hypoxia and immune markers to predict hepatocellular carcinoma treatment success non-invasively.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
New research reveals how the p53 tumor suppressor protein fights cancer by activating cell death pathways when oxygen levels drop.
Mouse study reveals the FXR bile acid receptor links gut microbes to arterial plaque in sleep apnea, hinting at new preventive targets.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
HIIT training studied in 52 men with prostate cancer on active surveillance to evaluate exercise benefits during watchful waiting.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
Review reveals how cardiolipin dysregulation drives glioblastoma survival and identifies potential therapeutic vulnerabilities.
CRC cells exploit a heme-SDH-CoQ axis to neutralize iron-induced oxidative stress, revealing new therapeutic targets.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
First study tests whether supervised exercise training is safe and beneficial for bladder cancer patients during treatment.
Researchers respond to peer critique of risk-based, non-invasive hepatocellular carcinoma surveillance in metabolic liver disease patients.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
Cancer cells that downregulate SMC4 enter a low-proliferation, diapause-like state that resists standard chemotherapy, revealing a dangerous survival mechanism.
New review reveals how targeting mitochondria in cancer cells could overcome immunotherapy resistance and enhance anti-tumor responses.
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.
